ERBB2 and neoplasm: To further investigate the potential of HER2 aptamers for molecular imaging in vivo, Gijs et al. [124] modified the aptamers into PET imaging agents by radiolabelling HeA2_1 and HeA2_3 with gallium-68 via a NOTA-chelator and evaluating the ex vivo biodistribution and tumour-targeting properties.